Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: Reaction pathways of potential relevance to Parkinson's disease

Chemical Research in Toxicology

Volumn 9, Issue 4, 1996, Pages 751-763

  Shen, Xue Ming ^a   Dryhurst, Glenn ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIAZINE DERIVATIVE; CYSTEINE; CYSTEINYLDOPA; DOPAMINE; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; QUINONE DERIVATIVE; SCAVENGER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYCLIC POTENTIOMETRY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; HYPERACTIVITY; LETHALITY; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; OXIDATION; PARKINSON DISEASE; REACTION ANALYSIS; SUBSTANTIA NIGRA; TREMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTEINE; CYSTEINYLDOPA; DOPAMINE; ELECTROCHEMISTRY; ELECTRODES; INJECTIONS, INTRAVENOUS; LETHAL DOSE 50; MICE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; OSMOLAR CONCENTRATION; OXIDATION-REDUCTION; PARKINSON DISEASE; SPECTROPHOTOMETRY, ULTRAVIOLET; THIAZINES;

ANIMALIA;

EID: 0029952619     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx960008f     Document Type: Article

References (42)

1. Hornykiewicz, O., and Kish, S. J. (1986) Biochemical pathophysiology of Parkinson's Disease. Adv. Neurol. 45, 19-34.
2. Hornykiewiez, O. (1989) Aging and neurotoxins as causative factors in idiopathic Parkinson's Disease - A critical analysis of neurochemical evidence. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 13, 319-328.
3. Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Lees, A. J., Jenner, P., and Marsden, C. D. (1989) Basal lipid peroxidation in substantial nigra is increased in Parkinson's Disease. J. Neurochem. 52, 381-389.
4. Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., and Marsden, C. D. (1990) Mitochondrial complex I deficiency in Parkinson's Disease. J. Neurochem. 54, 323-827.
5. Jenner, P., Dexter, D. T., Sian, J., Schapira, A. H. V., and Marsden, D. C. (1992) Oxidative stress as a cause of nigral cell death in Parkinson's Disease and Incidental Lewy Body Disease. Ann. Neurol. 32 (Suppl.), S82-S87.
6. Riederer, P., Sofic, E., Rausch, W. D., Schmidt, B., Reynolds, G., Jellinger, K., and Youdim, M. B. H. (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brain. J. Neurochem. 52, 515-520.
7. Fornstedt, B., Brun, A., Rosengren, E., and Carlsson, A. (1989) The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J. Neural Transm.: Parkinson's Dis. Dementia Sect. 1, 279-295.
8. Perry, T. L., and Yong, V. W. (1986) Idiopathic Parkinson's Disease, Progressive Supranuclear Palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67, 269-274.
9. Dexter, D. T., Sian, J., Jenner, P., and Marsden, C. D. (1993) Implications of alterations in trace element levels in brain in Parkinson's Disease and other neurological disorders affecting the basal ganglia. Adv. Neurol. 60, 273-281.
10. Sian, J., Dexter, D. T., Jenner, P., and Marsden, C. D. (1992) Glutathione-related enzymes in brain in basal ganglia degenerative disorders. Br. J. Pharmacol. 107 (Suppl.), 428P.
11. Orlowski, M., and Meister, A. (1979) The γ-glutamyl cycle. A possible transport system for amino acids. Proc. Natl. Acad. Sci. U.S.A. 67, 1248-1255.
12. Meister, A. (1974) Glutathione: metabolism and function via the γ-glutamyl cycle. Life Sci. 15, 177-190.
13. Barbeau, A., Roy, M., Paris, S., Cloutier, T., Plasse, L., and Poirier, J. (1985) Ecogenetics of Parkinson's Disease: 4-Hydroxylation of debrisoquine. Lancet, 1213-1216.
14. Barbeau, A. (1983) Etiology of Parkinson's Disease: A research strategy. Can. J. Neurol. Sci. 11, 24-28.
15. Tanner, C. M., Chen, B., Wang, W., Peng, M., Liu, Z., Liang, X., Kao, L.-C., Gilley, D. W., Goetz, C. G., and Schoenberg, B. S. (1989) Environmental factors and Parkinson's Disease. Neurology 39, 660-664.
16. Steventon, G. B., Heafield, M. T. E., Waring, R. H., and Williams, A. C. (1989) Xenobiotic metabolism in Parkinson's Disease. Neurology 39, 883-887.
17. Waring, R. H., Sturman, S. G., Smith, M. C. G., Steventon, G. B., Heafield, M. T. E., and Williams, A. C. (1989) S-Methylation in motoneuron disease and Parkinson's Disease. Lancet, 356-357.
18. Kinemuchi, H., Fowler, C. J., and Tipton, K. F. (1987) The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its relevance to Parkinson's Disease. Neurochem. Int. 11, 359-373.
19. Yong, V. W., Perry, T. L., and Krisman, A. A. (1985) Depletion of glutatione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment. Neurosci. Lett. 63, 56-60.
20. Ferraro, T. N., Golden, G. T., DeMattei, M., Hare, T. A., and Fariello, R. G. (1986) Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse. Neuropharmacology 25, 1071-1074.
21. Barbeau, A. (1984) Manganese and extrapyramidal disorders. Neurotoxicology 5, 13-36.
22. Liccione, J. L., and Maines, M. D. (1988) Selective vulnerability of glutathione metabolism and cellular defense mechanisms in rat striatum to manganese. J. Pharmacol. Exp. Ther. 247, 156-161.
23. Zhang, F., and Dryhurst, G. (1994) Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's Disease. J. Med. Chem. 37, 1084-1098.
24. Raps, S. P., Lai, J. C. K., Hertz, L., and Cooper, A. J. L. (1989) Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons. Brain Res. 493, 398-401.
25. Sagara, J.-I., Miura, K., and Bannai, S. (1993) Maintenance of neuronal glutathione by glial cells. J. Neurochem. 61, 1672-1676.
26. Graham, D. G. (1978) Oxidation pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633-643.
27. Rodgers, A. D., and Curzon, G. (1975) Melanin formation by human brain in vitro. J. Neurochem. 24, 1123-1129.
28. Tse, D. C. S., McCreery, R. L., and Adams, R. N. (1976) Potential oxidative pathways of brain catecholamines J. Med. Chem. 19, 37-40.
29. Carstam, R., Brinck, C., Hindemith-Augustsson, A., Rorsman, H., and Rosengren, E. (1991) The neuromelanin of the human substantia nigra. Biochim. Biophys. Acta 1097, 152-160.
30. Zhang, F., and Dryhurst, G. (1995) Influence of glutathione on the oxidation chemistry of the catecholaminergic neurotransmitter dopamine. J. Electroanal. Chem. Interfacial Electrochem. 398, 117-128.
31. Slivka, A., Mytilineou, C., and Cohen, G. (1987) Histochemical evaluation of glutathione in brain. Brain Res. 409, 275-284.
32. Miller, R. T., Lau, S. S., and Monks, T. J. (1995) Metabolism of 5-(glutathion-S-yl)-α-methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats. Chem. Res. Toxicol. 8, 634-641.
33. Owens, J. L., Marsh, H. A., and Dryhurst, G. (1978) Electrochemical oxidation of uric acid and xanthine. An investigation by cyclic voltammetry, double potential-step chronoamperometry, and thinlayer spectroelectrochemistry. J. Electroanal. Chem. Interfacial Electrochem. 91, 231-247.
34. Wrona, M. Z., Goyal, R. N., Turk, D. J., Blank, C. L., and Dryhurst, G. (1992) 5,5′-Dihydroxy-4,4′-bitryptamine: A potentially aberrant neurotoxic metabolite of serotonin. J. Neurochem. 59, 1392-1398.
35. Zhang, F., and Dryhurst, G. (1993) Oxidation chemistry of dopamine: Possible insights into the age-dependent loss of dopaminergic nigrostriatal neurons. Bioorg. Chem. 21, 392-410.
36. Zhang, F., and Dryhurst, G. (1995) Reactions of cysteine and cysteinyl derivatives with dopamine o-quinone and further insights into the oxidation chemistry of 5-S-cysteinyldopamine: Potential relevance to idiopathic Parkinson's Disease. Bioorg. Chem. 23, 193-216.
37. Dixon, W. J. (1965) The up-and-down method for small samples. J. Am. Stat. Assoc. 60, 967-978.
38. Halliwell, B., and Gutteridge, M. C. (1984) Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 219, 1-14.
39. Kastner, A., Hirsch, E. C., Lejeune, O., Javoy-Agid, F., Roscol, O., and Agid, Y. (1992) Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's Disease related to their neuromelanin content? J. Neurochem. 59, 1080-1089.
40. Hirsch, E. C., Graybiel, A. M., and Agid, Y. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's Disease. Nature 334, 345-348.
41. Fornstedt, B., and Carlsson, A. (1989) A marked rise in 5-S-cysteinyl-dopamine levels in guinea-pig striatum following reserpine treatment. J. Neural Transm. 76, 155-161.
42. Carlsson, A. (1990) Role of brain monoamines and other neurotransmitters in normal and pathological aging. Adv. Behav. Biol. 38A, 23-27.